In a recent study, the specific HSPA5 inhibitor HA15 was found to inhibit MM cell line growth, and displayed a synergistic effect when combined with bortezomib, significantly reducing MM cell viability by inducing ER stress [42]. The gene discussed is HSPA5; the disease is Miyoshi myopathy.